Study details
Enrolling now
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Uniquity One (UNI)
NCT IDNCT06496620ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
171
Study length
about 2.2 years
Ages
40–75
Locations
101 sites in AL, AZ, CA +28
About this study
This trial is testing a treatment called solrikitug, along with a placebo, in people with COPD. The goal is to see if solrikitug is safe and well-tolerated.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Receive Biological: Solrikitug high dose
- 3.Receive Biological: Solrikitug low dose
PhasePhase 2
Primary goalChange from baseline in blood eosinophil counts
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Change from baseline in blood eosinophil counts
Secondary: Change from baseline in FEV1 Adverse events (AEs) and serious adverse events (SAEs)
Body systems
Respiratory